Representing Primary Pharmaceutical Distributors – The Vital Linkin Healthcare
Share Print
banner capitol


HDMA reviews key priority issues and advocates on behalf of its pharmaceutical distributor members for standards, public policies and business processes that produce safe, innovative and cost-effective solutions.

  • Pharmaceutical Traceability

    The Drug Supply Chain Security Act (DSCSA, or Title II of the Drug Quality and Security Act) was enacted on November 27, 2013. The act replaces a 50-state patchwork of pedigree requirements with one federal traceability solution for prescription medicines and raises licensure standards across the U.S.

  • Prescription Drug Abuse and Diversion

    Prescription drug abuse is a serious healthcare challenge, and HDMA and its primary pharmaceutical distribution members are committed to being part of the solution and working collaboratively to address our country’s prescription drug abuse epidemic.

  • Taxes

    HDMA opposes repeal of the Last in, First Out (LIFO) accounting method and establishment of gross receipts taxes. Healthcare distribution represents a high-volume, low-profit margin business that is impacted disproportionately under certain tax proposals, including repeal of LIFO and instituting gross receipts taxes.

  • Reimbursement Issues

    HDMA supports the exclusion of customary prompt pay discounts from the calculation of the Average Sales Price (ASP) for Medicare Part B.

  • Distributor Licensure

    The introduction of counterfeit or adulterated medicines into the supply chain is a serious issue that could adversely affect the safety of prescription medicines and the health of patients. To that end, HDMA strongly supports tough, rigorous and consistent standards for state licensing of pharmaceutical distributors as required under federal law.

  • Drug Shortages

    Drug shortages have challenged regulatory and supply chain stakeholders alike in recent years. While the number of reported new shortages has decreased since 2011 (when they were at an all-time high of nearly 270) the FDA continues to see product shortages in the healthcare supply.

  • Emergency Preparedness and Response Efforts

    Pharmaceutical distributors have emergency preparedness plans in place to ensure continued operations in emergencies, and they actively work with their supply chain partners to solve challenges created by a pandemic or severe emergency scenario.

  • Grassroots Advocacy

    HDMA member companies' involvement in advocacy and legislative outreach is important to supporting, protecting and promoting the pharmaceutical distribution industry. To facilitate this outreach, HDMA has increased its grassroots efforts and encourages enhanced member participation in the legislative process.

  • Issue Experts

    HDMA staff members and the industry topics they focus on.

The Vital Link in Healthcare

HDMA's "Vital Link Toolkit" was created to inform and educate the public on the role of pharmaceutical distributors in the healthcare industry.


Read press releases, public testimony and executive statements about HDMA's efforts on behalf of pharmaceutical distributors and the entire supply chain.

Website design and development by, inc
© 2015 Healthcare Distribution Management Association. All rights reserved.
HDMA: M | C | D | NF